



SPARC/Sec/SE/2018-19/030

10th September 2018

To

The National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited

P J Towers,
Dalal street,
Mumbai - 400001

Ref: *Scrip Code: NSE: SPARC; BSE: 532872*

Sub: *Investor Presentation—Update on NCE & NDDS programs*

Dear Sir/ Madam,

Further to our letter No. SPARC/Sec/SE/2018-19/011 dated 4th July 2018 and letter No. SPARC/Sec/SE/2018-19/029 dated 4th September 2018 on the subject, we enclose herewith the Press Release on Update on the above mentioned subject being released by the Company, which is self-explanatory.

You are requested to kindly take the same on your record & disseminate the information through your website.

Yours faithfully,

For **Sun Pharma Advanced Research Company Limited**

Debashis Dey
Company Secretary

Encls: A/a.



Update on R&D Pipeline

September, 10, 2018, Mumbai: Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) on September 4, 2018, hosted a Management Presentation over a tele-conference and provided an update on its R&D pipeline. The audio playback of the conference call can be accessed until 22nd September 2018 using the following dial in details

Audio conference	Participants can dial-in on the number below: Toll Free Number (India) 18001203322 Toll Number +91 22 71945757/+91 22 66635757
Playback code	03571

The transcript of the conference call will be available at www.sparc.life shortly.

About SPARC (CIN:L73100GJ2006PLC047837)

Sun Pharma Advanced Research Company Ltd is an international pharmaceutical company engaged in research and development of novel drugs and delivery systems. More information about the company can be found at www.sparc.life.

Contact

Jaydeep Issrani
Tel +91 22 6645 5645, Ext 5787
Tel Direct +91 22 6645 5787
Mobile +91 9820216916
E mail jaydeep.issrani@sparcmail.com